Unbinding Kinetics of Muscarinic M3 Receptor Antagonists Explained by Metadynamics Simulations

被引:3
|
作者
Galvani, Francesca [1 ]
Pala, Daniele [2 ]
Cuzzolin, Alberto [2 ]
Scalvini, Laura [1 ]
Lodola, Alessio [1 ]
Mor, Marco [1 ,3 ]
Rizzi, Andrea [2 ]
机构
[1] Univ Parma, Dipartimento Sci Alimenti & Farmaco, I-43124 Parma, Italy
[2] Chiesi Farmaceut SpA, Chem Res & Drug Design Dept, I-43122 Parma, Italy
[3] Univ Parma, Microbiome Res Hub, I-43124 Parma, Italy
关键词
TARGET RESIDENCE TIME; DIARYL IMIDAZOLIDIN-2-ONE DERIVATIVES; ACCELERATED MOLECULAR-DYNAMICS; DISSOCIATION RATE; BINDING-KINETICS; DRUG; MECHANISM; DISCOVERY; DESIGN; SELECTIVITY;
D O I
10.1021/acs.jcim.3c00042
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
The residence time (RT), the time for which a drug remains bound to its biological target, is a critical parameter for drug design. The prediction of this key kinetic property has been proven to be challenging and computationally demanding in the framework of atomistic simulations. In the present work, we setup and applied two distinct metadynamics protocols to estimate the RTs of muscarinic M3 receptor antagonists. In the first method, derived from the conformational flooding approach, the kinetics of unbinding is retrieved from a physics-based parameter known as the acceleration factor alpha (i.e., the running average over time of the potential deposited in the bound state). Such an approach is expected to recover the absolute RT value for a compound of interest. In the second method, known as the tMETA-D approach, a qualitative estimation of the RT is given by the time of simulation required to drive the ligand from the binding site to the solvent bulk. This approach has been developed to reproduce the change of experimental RTs for compounds targeting the same target. Our analysis shows that both computational protocols are able to rank compounds in agreement with their experimental RTs. Quantitative structure-kinetics relationship (SKR) models can be identified and employed to predict the impact of a chemical modification on the experimental RT once a calibration study has been performed.
引用
收藏
页码:2842 / 2856
页数:15
相关论文
共 50 条
  • [1] Investigating the Unbinding of Muscarinic Antagonists from the Muscarinic 3 Receptor
    Buigues, Pedro J.
    Gehrke, Sascha
    Badaoui, Magd
    Dudas, Balint
    Mandana, Gaurav
    Qi, Tianyun
    Bottegoni, Giovanni
    Rosta, Edina
    JOURNAL OF CHEMICAL THEORY AND COMPUTATION, 2023, 19 (15) : 5260 - 5272
  • [2] Synthesis and optimization of novel and selective muscarinic M3 receptor antagonists
    Kumar, Naresh
    Kaur, Kirandeep
    Aeron, Shelly
    Dharmarajan, Sankaranarayanan
    Silamkoti, Arun D. V.
    Mehta, Anita
    Gupta, Suman
    Chugh, Anita
    Gupta, Jang B.
    Salman, Mohammad
    Palle, Venkata P.
    Cliffe, Ian A.
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2007, 17 (18) : 5256 - 5260
  • [3] Long-acting muscarinic M3 receptor antagonists -: GlaxoSmithKline
    Norman, Peter
    EXPERT OPINION ON THERAPEUTIC PATENTS, 2006, 16 (09) : 1315 - 1320
  • [4] Analogues of oxybutynin as M3 selective muscarinic receptor antagonists.
    Sarma, PKS
    Kumar, N
    Kaur, K
    Chugh, A
    Gupta, S
    Dutt, A
    Gupta, JB
    Mehta, A
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2004, 227 : U58 - U59
  • [5] Long-acting muscarinic M3 receptor antagonists -: Theravance
    Norman, Peter
    EXPERT OPINION ON THERAPEUTIC PATENTS, 2006, 16 (09) : 1321 - 1326
  • [6] Discovery of long acting inhaled muscarinic M3 receptor antagonists
    Baettig, Urs
    Collingwood, Steve
    Janus, Diana
    Devereux, Nick
    Stanley, Emily
    Cox, Brian
    McCarthy, Clive
    Charlton, Steven
    Leighton-Davis, Juliette
    Fozard, John R.
    Baur, Francois
    Farr, Dave
    Mazzoni, Lazzaro
    Patel, Viral
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2007, 233 : 750 - 750
  • [7] SYNTHESIS OF ANTAGONISTS OF MUSCARINIC (M3) RECEPTORS
    Broadley, Kenneth J.
    Davies, Robin H.
    Escargueil, Christine
    Lee, Alan T. L.
    Penson, Peter
    Thomas, Eric J.
    COLLECTION OF CZECHOSLOVAK CHEMICAL COMMUNICATIONS, 2011, 76 (07) : 781 - 801
  • [8] Discovery of Novel Potent Muscarinic M3 Receptor Antagonists with Proper Plasma Stability by Structural Recombination of Marketed M3 Antagonists
    Xiang, Zuojuan
    Liu, Jun
    Sun, Hongbin
    Wen, Xiaoan
    CHEMMEDCHEM, 2017, 12 (15) : 1173 - 1182
  • [9] At physiological concentrations, deoxycholic acid conjugates are M3 muscarinic receptor antagonists
    Raufman, JP
    Chen, Y
    Zimniak, P
    GASTROENTEROLOGY, 2001, 120 (05) : A357 - A358
  • [10] Quantifying the association and dissociation rates of unlabelled antagonists at the muscarinic M3 receptor
    Dowling, Mark R.
    Charlton, Steven J.
    BRITISH JOURNAL OF PHARMACOLOGY, 2006, 148 (07) : 927 - 937